Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Stefan, Aebi"'
Publikováno v:
Journal of Genetic Engineering and Biotechnology, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background About one-third of patients with estrogen receptor alpha (ERα)-positive breast cancer have tumors which are progesterone receptor (PR) negative. PR is an important prognostic factor in breast cancer. Patients with ERα-positive/P
Externí odkaz:
https://doaj.org/article/6e39a48d35504bc79ba51ef2d9ae9919
Autor:
Jane Bayani, Coralie Poncet, Cheryl Crozier, Anouk Neven, Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith Fraser, Florentine Hilbers, Ingrid Hedenfalk, Larissa Korde, Barbro Linderholm, John Martens, Lavinia Middleton, Melissa Murray, Catherine Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Aleksandra Peric, Peggy Porter, Carolien Schröder, Isabel T. Rubio, Kathryn J. Ruddy, Christi van Asperen, Danielle Van Den Weyngaert, Carolien van Deurzen, Elise van Leeuwen-Stok, Joanna Vermeij, Eric Winer, Sharon H. Giordano, Fatima Cardoso, John M. S. Bartlett
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to g
Externí odkaz:
https://doaj.org/article/39b74ac02205476a9300ff36cbb33d6d
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The implementation of pharmacogenetic testing into clinical practice has been a slow process so far. Here, we review the implementation of pre-treatment testing of dihydropyrimidine dehydrogenase gene (DPYD) risk variants to prevent early-onset fluor
Externí odkaz:
https://doaj.org/article/6f384ba119b844bcbdf04ccc302131f9
Publikováno v:
Breast, Vol 62, Iss , Pp S58-S62 (2022)
Locally advanced breast cancer (LABC) is defined here as inoperable breast adenocarcinoma without distant metastases. Patients with LABC require a multidisciplinary approach. Given the risk of distant metastasis, staging exams are necessary. The inci
Externí odkaz:
https://doaj.org/article/569723842c3e456aa892dc887e58dc82
Autor:
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 2
Externí odkaz:
https://doaj.org/article/3a71b23e5f6e4fdeb49b83bd63c454c7
Autor:
Mariana Bustamante Eduardo, Vlad Popovici, Sara Imboden, Stefan Aebi, Nadja Ballabio, Hans Jörg Altermatt, Andreas Günthert, Rolf Jaggi
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
Abstract Background Breast cancer is a leading cause of cancer-related death in women worldwide. Despite extensive studies in all areas of basic, clinical and applied research, accurate prognosis remains elusive, thus leading to overtreatment of many
Externí odkaz:
https://doaj.org/article/06e512fcaf37410a8cb7a4f963a11cc2
Autor:
Danielle B. Zakon, Coralie Poncet, Fatima Cardoso, Neven Anouk, Vicente Valero, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith Fraser, Carmela Caballero, Ingrid A. Hedenfalk, Larissa A. Korde, Barbro Linderholm, John WM Martens, Lavinia P. Middleton, Melissa Murray, Catherine M. Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Melanie Beauvois, Peggy Porter, Carolien P. Schroder, Isabel T. Rubio, Kathryn Ruddy, Christi van Asperen, Danielle Van Den Weyngaert, Carolien HM van Deurzen, Elise van Leeuwen-Stok, Joanna M. Vermeij, John MS Bartlett, Antonio C. Wolff, Sharon H. Giordano, W. Fraser Symmans
Publikováno v:
Cancer Research. 83:PD6-11
Introduction Breast cancer is uncommon in men. Almost all male breast cancers are hormone receptor-positive, HER2-negative, although the pathogenesis is not always attributable to an endocrine condition. A few studies have compared biological charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5786f2f1b9efbca41eb96cade72cbbf2
https://doi.org/10.1158/1538-7445.sabcs22-pd6-11
https://doi.org/10.1158/1538-7445.sabcs22-pd6-11
Autor:
Seid Hamzic, Stefan Aebi, Markus Joerger, Michael Montemurro, Marc Ansari, Ursula Amstutz, Carlo Largiadèr
Publikováno v:
Swiss Medical Weekly, Vol 150, Iss 4748 (2020)
Fluoropyrimidines (FPs), mainly 5-fluorouracil (5-FU) and its oral prodrug capecitabine (Cap), remain the backbone of the treatment of many different solid tumors. Despite their broad use in clinical routine, 10–40% of patients experience severe, a
Externí odkaz:
https://doaj.org/article/0ef46732bff3495b8511d835fbe22eef
Autor:
Edoardo Isnaldi, François Richard, Giuseppe Marano, Patrizia Boracchi, Marion Maetens, Giuseppe Floris, Guy Jerusalem, Andrea Gombos, Alastair M. Thompson, Erika Hitre, Stefan Aebi, Marco Colleoni, Patrizia Dell’Orto, Roswitha Kammler, Patrick Neven, Giuseppe Viale, Meredith Regan, Elia Biganzoli, Christine Desmedt
Publikováno v:
Cancer Research. 83:P3-05
Background: The risk of late distant recurrence (≥ 5 years) in post-menopausal patients with ER+ BC remains significant even after standard adjuvant endocrine therapy (ET). Obesity, which has reached high proportions in Western Countries, is one of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25e851e6c26e987722564afa6c2a1bb9
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-28
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-28
Autor:
Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, The Swiss Group for Clinical Cancer Research (SAKK)
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). Methods SAKK 26/10 is a multicenter, prospective cohort study
Externí odkaz:
https://doaj.org/article/c9a8ea8a27db4f48921538bf341f9e66